6533b873fe1ef96bd12d4d5c
RESEARCH PRODUCT
Integrating theoretical and experimental permeability estimations for provisional biopharmaceutical classification: Application to the WHO essential medicines.
Yudileidy Brito-ferrerClaudia Miranda-pérez De AlejoRosario Hernández-armengolMirna Fernández CerveraHai Pham TheMiguel ÁNgel Cabrera-pérezMiguel ÁNgel Cabrera-pérezsubject
In vitro dissolutionTheoretical modelsPharmaceutical Science02 engineering and technologyBioequivalenceIn Vitro TechniquesWorld Health Organization030226 pharmacology & pharmacyModels BiologicalDosage formPermeabilityBiopharmaceuticsMadin Darby Canine Kidney Cells03 medical and health sciences0302 clinical medicineDogsAnimalsHumansPharmacology (medical)Intestinal MucosaMathematicsPharmacologyGeneral Medicine021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemBioavailabilityRatsPermeability (earth sciences)BiopharmaceuticalCaco-2 Cells0210 nano-technologyBiological systemDrugs Essentialdescription
The accuracy of the provisional estimation of the Biopharmaceutics Classification System (BCS) is heavily influenced by the permeability measurement. In this study, several theoretical and experimental models currently employed for BCS permeability classification have been analysed. The experimental models included the in situ rat intestinal perfusion, the ex vivo rat intestinal tissue in an Ussing chamber, the MDCK and Caco-2 cell monolayers, and the parallel artificial membrane (PAMPA). The theoretical models included the octanol-water partition coefficient and the QSPeR (Quantitative Structure-Permeability Relationship) model recently developed. For model validation, a dataset of 43 compounds has been recompiled and analysed for the suitability for BCS permeability classification in comparison with the use of human intestinal absorption and oral bioavailability values. The application of the final model, based on a majority voting system showed a 95.3% accuracy for predicting human permeability. Finally, the present approach was applied to the 186 orally administered drugs in immediate-release dosage forms of the WHO Model List of Essential Medicines. The percentages of the drugs that were provisionally classified as BCS Class I and Class III was 62.4%, suggesting that in vivo bioequivalence (BE) may potentially be assured with a less expensive and more easily implemented in vitro dissolution test, ensuring the efficiency and quality of pharmaceutical products. The results of the current study improve the accuracy of provisional BCS classification by combining different permeability models.
year | journal | country | edition | language |
---|---|---|---|---|
2018-07-01 | Biopharmaceuticsdrug disposition |